Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GALT
Strong SellSinkerGalectin Therapeutics Inc. · Healthcare · United States · $405M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the research and development of therapies for fibrotic liver diseases and cancer. The company's competitive moat is centered on its proprietary galectin-3 inhibitor, belapectin, which is designed to target the root causes of NASH cirrhosis and enhance cancer immunotherapies. It operates as a highly specialized biotechnology player addressing complex, high-value medical indications with significant unmet needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.65 | -0.74 | -0.76 | -0.48 | — | -0.43 | -0.30 | -0.23 | — |
| Shares | 59.4M | 61.9M | 63.2M | 65.2M | +9.7% | — | — | — | — |
| Debt | 39.9M | 71.8M | 106.2M | 133.8M | 49.7% | 144.0M | — | — | — |
| Equity | -32.2M | -60.2M | -103.1M | -126.2M | — | — | — | — | — |
| Op CF | -31.1M | -33.0M | -41.8M | -23.9M | — | -15.9M | — | — | — |
| Inv CF | 0 | 0 | 0 | 0 | — | — | — | — | — |
| Fin CF | 10.0M | 40.0M | 31.2M | 26.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GALT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GALT | Galectin Therapeutics Inc.(you) | $405M | 11 | Strong Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $424M | 10 | Strong Sell |
| ENTA | Enanta Pharmaceuticals, Inc. | $396M | 13 | Strong Sell |
| LXEO | Lexeo Therapeutics, Inc. | $399M | 7 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 16 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $339M | 9 | Strong Sell |
| UPB | Upstream Bio, Inc. | $366M | 8 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 10 | Strong Sell |
| EDIT | Editas Medicine, Inc. | $485M | 14 | Strong Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%